DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-073/S-028
NDA 21-842/S-002

Takeda Global Research & Development Center, Inc.
Attention: Mary Jo Pritza, MPH, PharmD
Manager, Regulatory Affairs
One Takeda Parkway
Deerfield, IL 60015-2235

Dear Ms. Pritza:

Please refer to your supplemental new drug applications dated May 30, 2006, received May 31, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for:

> Actos® (pioglitazone HCl) tablets, 15 mg, 30 mg, and 45 mg (NDA 21-073 and,
> Actoplus Met™ (pioglitazone HCl + metformin HCl) fixed-dose combination tablets, 15 mg/500 mg and 15 mg/850 mg (NDA 21-842).

These supplemental applications proposed to update the **CLINICAL PHARMACOLOGY** section**, Drug-Drug Interactions** subsection and **PRECAUTIONS** sections of the package insert.

We completed our review of these applications. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package inserts) submitted (via electronic mail) on November 3, 2006.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions "**FPL for approved supplements NDA 21-073/S-028 and NDA 21-842/S-002**." Approval of these submissions by FDA is not required before the labeling is used.

If you issue a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to theses NDAs and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Jena Weber, Project Manager, at 301-796-1306.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure (package inserts)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Parks

11/4/2006 11:42:19 AM